MedTrace Logo

First in Human, Single Ascending Dose Study

NCT05844592 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-05-06

No results posted yet for this study

Summary

The goal of this study is to evaluate the safety and tolerability of single ascending oral doses of INV-101 in healthy adult subjects.

Conditions

Interventions

DRUG

INV-101

subjects will be randomized 3:1 ratio

Sponsors & Collaborators

  • Innovo Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Minjeong Kim, Master · New Drug development Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-21
Primary Completion
2022-07-16
Completion
2022-08-31
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05844592 on ClinicalTrials.gov